In an age of financial constraint and austerity questions of value are inevitably asked of pharma.
David Coleiro, Paula Lashley and John Grime take a look at how society values medicines, the role of health technology assessment (HTA) bodies like NICE, what value means when it comes to end-of-life care and ask whether the need for cost containment has blurred the perception of value.
David Coleiro is a Partner and Paula Lashley and John Grime are Consultants at Strategic North, a healthcare marketing strategy consultancy that works with clients to build inspiring, joined-up strategic stories.
• This article first appeared in the September 2012 issue of PME (Pharmaceutical Market Europe) and can be viewed online or downloaded as a pdf to read later
Value_of_medicines_PME_Sept12.pdf
PDF File: 1.6 MB
Address:
Media House
Richmond Road
Bowdon
Altrincham
WA14 2TT
United Kingdom